Abstract
Introduction: Bulevirtide (BLV) has been recently approved for the treatment of HDV-related chronic hepatitis or compensated cirrhosis in Europe, but its effectiveness and safety in patients with advanced cirrhosis and severe portal hypertension are still unknown.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have